The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316).
 
Susanne M. Arnold
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Genentech (Inst); Stem CentRx (Inst)
 
Kari Chansky
No Relationships to Disclose
 
Maria Quintos Baggstrom
Research Funding - ACCRU (Inst); Alliance for Clinical Trials in Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); MedImmune (Inst); Millennium (Inst)
 
Michael A. Thompson
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - AIM Specialty Health; Celgene; GlaxoSmithKline; Strata Oncology; Syapse; Takeda; VIA Oncology
Patents, Royalties, Other Intellectual Property - UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle)
Travel, Accommodations, Expenses - GlaxoSmithKline; Syapse; Takeda
Other Relationship - Doximity
 
Rachel E. Sanborn
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - Five Prime Therapeutics; Janssen Oncology
 
John Villano
No Relationships to Disclose
 
Saiama Naheed Waqar
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
John Turner Hamm
Consulting or Advisory Role - Genentech/Roche; Meda Pharmaceuticals; Pfizer
Speakers' Bureau - Janssen
Research Funding - Various (Inst)
 
Mark Leggas
No Relationships to Disclose
 
Maurice Willis
Honoraria - Lilly; Mitra Biotech; Mitra Biotech
 
Joseph G Rosales
No Relationships to Disclose
 
John Crowley
No Relationships to Disclose